{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Table 7.2', 'Summary of TEAEs Reported in at Least 5% of Subjects in Teprotumumab', 'Treatment Group and % is Greater Than Placebo', 'Placebo', 'Teprotumumab', 'N=44', 'N=43', 'Summary Details for TEAEs', 'TEAEs', 'n (%)', 'n (%)', 'in Teprotumumab Group', 'Any TEAE', '32 (72.7)', '32 (74.4)', 'Nausea', '4 (9.1)', '8 (18.6)', 'Generally mild and reported after first/second infusions', 'Muscle spasms', '2 (4.5)', '8 (18.6)', 'Intermittent, 2/8 cases experienced for >1 week and treated with', 'muscle relaxants', 'Diarrhea', '2 (4.5)', '6 (14.0)', 'Treatment required in 2/6 cases, 1 designated an SAE (see', 'below)', 'Hyperglycemia', '2 (4.5)', '5 (11.6)', 'Mechanism-based AE', 'Alopecia', '2 (4.5)', '3 (7.0)', 'All mild and no treatment required', 'Dry skin', '0', '3 (7.0)', 'All mild, one case used topical dry skin cream', 'Dysgeusia', '0', '3 (7.0)', 'For 2/3 cases a transient \"metallic\" taste on Days 1-2', 'Headache', '2 (4.5)', '3 (7.0)', 'Generally mild, one subject took paracetamol', 'Paresthesia', '0', '3 (7.0)', '\"Tingling\" reported in nose, feet or chest; variable onset and in', '2/3 cases occurred on 1 day', 'Hearing impaired', '0', '3 (7.0)', 'Disparate symptoms, onset and duration (i.e., one unilateral with', 'onset 16 weeks after end of therapy, one mild bilateral that', 'resolved, one intermittent in a subject with positive history of', 'tinnitus)', 'Weight loss', '0', '3 (7.0)', 'Variable timing; decreases range from 5-9 lb.', 'No deaths occurred in TED01RV, and early terminations were comparable in each treatment', 'group (6/group). SAEs occurred in 5/43 (11.6%) of the subjects in the teprotumumab group and', '1/45 (2.2%) of the subjects in the placebo group (Table 7.3). Two SAEs in the teprotumumab', 'group were categorized by the Investigators as \"possibly related\" (diarrhea and mental', \"confusion, which had a provisional diagnosis of Hashimoto's encephalopathy); the remaining\", 'were categorized as \"unrelated\". In the teprotumumab group, 4 discontinuations for SAEs', 'occurred after the following number of infusions: diarrhea after 6 infusions; inflammatory bowel', \"disease (IBD) after 7 infusions; Escherichia coli sepsis after 3 infusions; and Hashimoto's\", 'encephalopathy after 6 infusions.', 'Clinically relevant levels of ADAs were not detected in any subject.', 'In the Phase 2 study, three non-serious adverse events (AEs) involving hearing impairment', 'occurred in the teprotumumab group. A 59-year-old subject experienced acute bilateral hearing', 'abnormality approximately 12 weeks following the 1st infusion of teprotumumab with resolution', 'several months following the last infusion. A second 43-year-old subject with eustachian tube', 'dysfunction experienced hearing loss nearly 4 months following discontinuation of', 'teprotumumab. A third 60-year-old subject with a history of tinnitus experienced hearing loss', 'following loud noise exposure. While a causal relationship between teprotumumab and the event', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 56 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'of hearing impairment is considered doubtful, it may be reasonable to avoid ototoxic drugs while', 'receiving teprotumumab, if possible.', 'Table 7.3', 'Summary of SAEs Reported in Either Treatment Group by Preferred Term', 'Placebo', 'Teprotumumab', 'N=44', 'N=43', 'Summary Details for SAEs in', 'SAE', 'Teprotumumab Group', 'n (%)', 'n (%)', 'Any SAE', '1 (2.3)', '5 (11.6)', 'Optic neuropathy', '1 (2.3)', '0', 'Diarrhea', '0', '1 (2.3)', 'Severe diarrhea in one subject with 6-month', 'history of ulcerative colitis - hospitalized', 'IBD', '0', '1 (2.3)', 'Subject with recent diagnosis of ileitis and colitis,', 'diagnosed and treated for IBD while on therapy -', 'hospitalized', 'Escherichia sepsis', '0', '1 (2.3)', 'E. coli infection of unknown origin, treated with', 'IV antibiotics - hospitalized', \"Suspected Hashimoto's\", '0', '1 (2.3)', 'Provisional diagnosis for episodic mental', 'encephalopathy', 'confusion with no other neurological symptoms -', 'hospitalized', 'Urinary retention', '0', '1 (2.3)', 'Occurred following an inguinal herniorrhaphy -', 'hospitalized', 'AEs Previously Identified as Special Interest', 'AESIs identified in the oncology studies (infusion-associated events, hyperglycemia,', 'thrombocytopenia, and anemia; see Section 7.1.3.4.5.5) were examined in TED01RV.', 'Infusion-associated AEs were reported for 1 teprotumumab-treated subject (facial flushing and', 'warmth with concomitant elevated heart rate and blood pressure at the end of the 90-minute', 'observation period after the second infusion). At the third infusion visit, the subject was pre-', 'medicated with diphenhydramine, dexamethasone, famotidine and Tylenol and had a similar', 'reaction prior to the study drug infusion.', 'Among non-diabetic subjects, hyperglycemia occurred at comparable rates in both treatment', 'groups and was uniformly Grade 1 and intermittent. Among diabetic subjects, Grade 2 or 3', 'hyperglycemia occurred in some teprotumumab-treated subjects; this was well-controlled after', 'diabetes medication adjustment. Glycemic control, as assessed by HbA1c, was at baseline levels', 'following the treatment phase for all subjects in the teprotumumab group.', 'No subjects experienced thrombocytopenia as an AE. There were small differences in the', 'population means of platelet values in the teprotumumab group compared to placebo that were', 'not considered clinically significant and, importantly, diminished with continued dosing.', 'No subjects experienced anemia as an AE.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 57 of 117']\n\n###\n\n", "completion": "END"}